Search

David I Alagille

from Woodbridge, CT
Age ~50
Get Report
Also known as:
Dave Alagille
Phone and address:
12 Cedar Rd, New Haven, CT 06525
Connected to:
Larry M Alagna, 67Lindsey J Alagna, 31Salvatore Alagna, 44Diana D Alagood, 79Dineth A AlahakoonHatem Alahamad, 45Vindya P Alahapperuma, 46Antony Alaharasan, 85Durga S Alahari, 54Eugene K Alahaydoian, 83

David Alagille Phones & Addresses

  • 12 Cedar Rd, Woodbridge, CT 06525
  • 11 Harbour Close, New Haven, CT 06519 (203) 752-0013
  • 488 Chapel St, New Haven, CT 06511 (203) 752-0013
  • Oxford, CT
  • 171 Hogs Back Rd, Oxford, CT 06478

Work

Position: Professional/Technical

Education

Degree: High school graduate or higher

Publications

Us Patents

Compounds And Amyloid Probes Thereof For Therapeutic And Imaging Uses

US Patent:
20070258887, Nov 8, 2007
Filed:
May 8, 2007
Appl. No.:
11/800986
Inventors:
Gilles Tamagnan - Woodbridge CT, US
David Alagille - New Haven CT, US
Herve Costa - New Haven CT, US
International Classification:
A61K 51/00
C07D 498/02
C07D 487/04
C07D 277/84
US Classification:
424001110, 544281000, 546114000, 546119000, 546329000, 548150000, 548152000, 546270100, 548257000
Abstract:
The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus. The compounds and amyloid probes of the invention include analogs, salts, pharmaceutical compositions, derivatives, prodrugs, racemic mixtures or tautomeric forms thereof.

Compounds And Amyloid Probes Thereof For Therapeutic And Imaging Uses

US Patent:
20100143251, Jun 10, 2010
Filed:
Feb 17, 2010
Appl. No.:
12/706787
Inventors:
Gilles D. Tamagnan - Woodbridge CT, US
David Alagille - New Haven CT, US
Herve Da Costa - New Haven CT, US
International Classification:
A61K 51/00
A61K 49/00
C12Q 1/02
A61K 31/519
A61K 31/437
C07D 487/04
C07D 491/04
US Classification:
424 181, 424 91, 424 931, 424 96, 435 29, 5142591, 514302, 544281, 546115
Abstract:
The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus. The compounds and amyloid probes of the invention include analogs, salts, pharmaceutical compositions, derivatives, prodrugs, racemic mixtures or tautomeric forms thereof.

Compounds And Amyloid Probes Thereof For Therapeutic And Imaging Uses

US Patent:
20100143253, Jun 10, 2010
Filed:
Feb 17, 2010
Appl. No.:
12/706916
Inventors:
Gilles D. Tamagnan - Woodbridge CT, US
David Alagille - New Haven CT, US
Herve Da Costa - New Haven CT, US
International Classification:
A61K 51/04
C07D 471/04
C07D 249/18
C07D 513/14
C07D 263/30
A61K 31/437
A61K 31/4192
A61K 31/429
A61K 31/421
A61P 25/28
US Classification:
424 189, 546121, 548257, 548151, 548215, 514300, 514359, 514366, 514374, 424 181, 424 185
Abstract:
The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus. The compounds and amyloid probes of the invention include analogs, salts, pharmaceutical compositions, derivatives, prodrugs, racemic mixtures or tautomeric forms thereof.

Compounds And Amyloid Probes Thereof For Therapeutic And Imaging Uses

US Patent:
20100150833, Jun 17, 2010
Filed:
Feb 17, 2010
Appl. No.:
12/706906
Inventors:
Gilles D. Tamagnan - Woodbridge CT, US
David Alagille - New Haven CT, US
Herve Da Costa - New Haven CT, US
International Classification:
A61K 51/04
C07D 513/02
A61K 31/429
A61K 49/00
A61K 49/06
G01N 33/53
A61P 25/28
US Classification:
424 165, 548151, 514366, 424 91, 424 93, 424 96, 435 721
Abstract:
The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus. The compounds and amyloid probes of the invention include analogs, salts, pharmaceutical compositions, derivatives, prodrugs, racemic mixtures or tautomeric forms thereof.
Control profile
David I Alagille from Woodbridge, CT, age ~50 Get Report